Evidence-based summary compiled from WHO, CDC, ECDC, Mayo Clinic, TGA & Australian health authorities — May 2026
Hantaviruses are a family of RNA viruses carried mainly by specific rodent species (mice, rats, voles). The rodents remain healthy but shed the virus in urine, droppings, and saliva. Humans become infected primarily by inhaling aerosolized particles from contaminated dust. The infection can cause two distinct severe diseases: Haemorrhagic Fever with Renal Syndrome (HFRS) — prevalent in Europe and Asia — which affects the kidneys, and Hantavirus Pulmonary Syndrome (HPS) — found mainly in the Americas — which causes rapid respiratory failure. Case-fatality rates: HPS can exceed 35% in severe outbreaks; for HFRS, Hantaan virus (Asia) reaches up to 15%, while milder European Puumala virus stays below 1%.
Infection most often occurs when people inhale dust contaminated with rodent excreta, especially while cleaning sheds, cabins, or vacant spaces. Less common routes include direct contact with broken skin, rodent bites, or ingesting contaminated food. Person-to-person transmission is exceptionally rare; among all hantaviruses, only the Andes virus (South America) has documented limited human-to-human spread via close contact or healthcare settings.
Core prevention strategies:
Seal entry points: close gaps >0.6 cm in walls, doors, foundations to keep rodents out.
Eliminate food sources: store food, pet feed and water in rodent-proof containers.
Clean safely: never sweep or vacuum dry droppings/urine. Instead, ventilate the area, wear mask+gloves, spray with disinfectant (bleach solution), then wipe with damp cloth.
High-risk groups: field workers, campers, pest controllers should take extra precautions.
There is currently no specific antiviral treatment approved worldwide. Patient care relies on early intensive supportive therapy (oxygen/ventilation, fluid management, dialysis if needed). No widely licensed human vaccine exists globally, except China offers an inactivated HFRS vaccine for high-risk regions.
Australia occupies a distinctive position on the global hantavirus map: it is the only inhabited continent where no locally acquired human hantavirus infection has ever been documented. The Australian health authorities (including the Doherty Institute, CSIRO, and state health departments) emphasize that hantaviruses are "extremely unlikely" to establish endemic transmission because each hantavirus is tightly co-evolved with a specific rodent reservoir. "Spillover" to Australian native rodents or introduced rats has not been observed, making it improbable for the virus to become established.
Nevertheless, Australia maintains robust preparedness. The Victorian Infectious Diseases Reference Laboratory (VIDRL) offers PCR and serological testing for returning travellers with compatible symptoms. Importantly, diagnostic test kits and laboratory procedures are regulated by the Therapeutic Goods Administration (TGA) — Australia's counterpart to the FDA — which ensures the safety, performance, and quality of in vitro diagnostic medical devices used for hantavirus detection. TGA’s oversight guarantees that any test deployed in Australian clinical settings meets stringent standards.
In May 2026, an outbreak of Andes virus causing HPS was reported aboard the cruise ship "MS Hondius" in the Antarctic region. The World Health Organization (WHO) and the European CDC (ECDC) assessed the global risk as low. The ECDC notes that Andes virus requires prolonged, close interpersonal contact for human-to-human transmission, and no sustained community spread has been identified. European population risk remains “very low”. WHO has deployed experts to support response activities. In parallel, Chinese CDC and Australian health departments are closely monitoring the event. For Australians returning from affected areas, any travellers developing fever, shortness of breath, or reduced urine output together with possible rodent contact history should seek prompt medical attention and mention their exposure history.
For the general public (outside the endemic regions of the Americas or rural Asia), the risk of hantavirus infection remains minimal. The United States CDC states that hantavirus disease is rare — only 890 laboratory-confirmed cases reported between 1993–2023 nationwide.
Initial signs often mimic influenza: fever, chills, muscle aches, headache, and sometimes gastrointestinal upset. In HPS, symptoms evolve quickly to cough, shortness of breath, and low oxygen levels — life-threatening within days. In HFRS, look for "three pains" (headache, low-back pain, eye socket pain), facial flushing, and later signs of bleeding or reduced urine output. Anyone with compatible symptoms and a history of rodent exposure (cleaning old buildings, camping, rural work) should see a doctor and alert them to potential hantavirus exposure.
US CDC – Hantavirus: https://www.cdc.gov/hantavirus/about/index.html
World Health Organization (WHO) outbreak toolkit: https://www.who.int/emergencies/outbreak-toolkit/disease-outbreak-toolboxes/hantavirus-outbreak-toolbox
Mayo Clinic – Hantavirus Pulmonary Syndrome: https://www.mayoclinic.org/diseases-conditions/hantavirus-pulmonary-syndrome/symptoms-causes/syc-20351838
European CDC (ECDC): https://www.ecdc.europa.eu
Chinese CDC (China): https://www.chinacdc.cn/jkkp/crb/qtcr/
Doherty Institute (Australia): https://www.doherty.edu.au/articles/hantavirus-your-questions-answered/
Australian CDC (Communicable Diseases Network Australia): https://www.cdc.gov.au/newsroom/news-and-articles/hantavirus-infection-reported-cruise-ship-atlantic
CSIRO Australia – Explainer: https://www.csiro.au/en/news/all/articles/2026/may/hantavirus-explainer
Therapeutic Goods Administration (TGA) – Medical device regulation: https://www.tga.gov.au
Disclaimer: This content is for educational and scientific communication purposes only. It does not replace professional medical advice. If you have concerning symptoms, please contact a healthcare provider.
Last updated: May 2026. Based on latest WHO, CDC, ECDC, TGA and Australian health agency bulletins.
